Results 51 to 60 of about 2,712,287 (341)
Headache, 2020 To evaluate the efficacy, tolerability, and safety of eptinezumab 100 and 300 mg compared with placebo in patients with the dual diagnosis of chronic migraine (CM) and medication‐overuse headache (MOH).
H. Diener +10 more
semanticscholar +1 more source
Cognitive performance in chronic migraine [PDF]
Arquivos de Neuro-Psiquiatria, 2020 Migraine is a ubiquitous disorder that affects 15% of the world population, particularly women during their most productive years. Migraine produces a variety of symptoms, but its most common presentation consists of recurrent attacks of disabling headaches associated to nausea and intolerance to all sensory stimuli.
openaire +5 more sources
Journal of Comorbidity, 2017 Background: Chronic migraine is common but there is limited knowledge on associated comorbidities. Objectives: To examine mental and physical comorbidities in chronic migraine and the influence of socioeconomic status in a large, nationally ...
Gary McLean, Stewart W. Mercer
doaj +1 more source
The Journal of Headache and Pain, 2021 Background Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-related peptide, has demonstrated a significant reduction in monthly migraine headache days compared with placebo. Here, we analyze data from 3 randomized clinical trials
Michael Ament +6 more
doaj +1 more source
Defining the Differences Between Episodic Migraine and Chronic Migraine [PDF]
Current Pain and Headache Reports, 2011 Chronic migraine (CM) and episodic migraine (EM) are part of the spectrum of migraine disorders, but they are distinct clinical entities. Population-based studies have shown that those with CM demonstrate higher individual and societal burden because they are significantly more disabled than those with EM and have greater impaired quality of life both ...
Katsarava, Zaza +3 more
openaire +2 more sources
Chronic Migraine in Adolescence
, 2020 Chronic migraine (CM) is a clinically and epidemiologically important disease that generates considerable impairment to those affected by it, since there is evidence of higher incidence of depression, anxiety, and chronic pain in patients with this condition.
Daniel Albiero Piélak +5 more
openaire +4 more sources
Cortical Excitability in Chronic Migraine [PDF]
Current Pain and Headache Reports, 2011 A proportion of episodic migraine patients experiences a progressive increase in attack frequency leading to chronic migraine (CM). The most frequent external factor that leads to headache chronification is medication overuse. The neurobiological bases of headache chronification and of the vicious circle of medication overconsumption are not completely
COPPOLA, GIANLUCA, Jean Schoenen
openaire +4 more sources
Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal
The Journal of Headache and Pain, 2018 Background Calcitonin gene-related peptide (CGRP) has been reported as elevated in chronic migraine. We aimed to validate the role of interictal serum CGRP concentration in peripheral blood samples as a biomarker of chronic migraine.
Mi Ji Lee +4 more
doaj +1 more source
Scientific Reports, 2023 To evaluate whether preventive treatment can modify endothelial and oxidative biomarkers of vascular disease risk in patients with high-frequency episodic and chronic migraine.
Cristina González Mingot +10 more
doaj +1 more source
Phenotyping Healthcare Use 2–3 Decades Before the First Multiple Sclerosis Demyelinating Event
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Phenotype hospital, physician, and emergency department (ED) visits by diagnoses and specialty up to 29 years pre‐multiple sclerosis (MS) onset versus a matched population without MS. Methods We identified people with MS (PwMS) using population‐based administrative data from Ontario, Canada (1991–2020).
Helen Tremlett +8 more
wiley +1 more source